Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna , Inc. (NASDAQ:MRNA) today confirmed that it has won a tender to supply its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia. The agreement, valid for up to four ...

Although the protection against COVID-19 still offers a significant ... their cash runway to at least 16 months, presuming no revenues in 2025. Overall, Moderna's transition from pandemic to ...

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through ...

Earlier this month, Moderna convinced investor to send the stock ... Moderna was thriving during Covid-19 pandemic when its mRNA-based Covid-19 vaccine was successfully distributed to cater ...

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Moderna is a leader in the creation of the field of mRNA medicine. Through the ...

Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North ...